Clinical Dilemma of Small Intracranial Aneurysms

Managing small intracranial aneurysms represents a significant clinical dilemma in neurosurgery and interventional neuroradiology today. Clinicians frequently identify these diminutive vascular outpouchings measuring five millimeters or less during routine neuroimaging for unrelated symptoms. Although historical studies suggested diminutive lesions carry negligible rupture risk, real-world registry data challenge this assumption. Consequently, neurovascular specialists must confront vastly disparate clinical presentations, ranging from completely asymptomatic incidentalomas to devastating aneurysmal subarachnoid hemorrhage. Therefore, distinguishing the baseline risk profile between ruptured and unruptured lesions is essential for timely, life-saving decision-making. In addition, geographical, socioeconomic, and institutional factors strongly influence acute healthcare delivery and clinical outcomes across diverse global populations. Latin America, in particular, represents an understudied demographic where critical care infrastructure, specialist availability, and interventional resources vary considerably between centers. Understanding true in-hospital mortality across this spectrum is necessary to optimize triage pathways, allocate resources, and reduce preventable deaths. Furthermore, defining these parameters helps neurovascular teams tailor acute monitoring and intervention protocols appropriately. Hence, neurovascular clinicians require robust multicenter evidence dissecting early clinical trajectories, hospital mortality, and complication profiles in this patient subset.

Key Findings From the Multicenter Cohort Study

A multicenter observational study recently evaluated 1,519 patients harboring small intracranial aneurysms across eight tertiary referral centers in five Latin American nations. The investigators analyzed consecutive admissions between 2017 and 2023 to capture modern endovascular and microsurgical management patterns. Specifically, the researchers stratified the cohort based on rupture status at initial clinical presentation. Among the participants, 421 patients presented with acute aneurysmal subarachnoid hemorrhage, representing twenty-eight percent of the total population. Meanwhile, 1,098 patients presented with unruptured aneurysms, constituting seventy-two percent of the evaluated cohort. Overall in-hospital mortality reached seven percent across the combined study cohort. However, patient stratification revealed a stark disparity in early fatal outcomes. Patients presenting with ruptured lesions suffered an in-hospital mortality rate of eighteen percent. In contrast, patients harboring unruptured aneurysms experienced an in-hospital mortality rate of only three percent. Furthermore, clinical teams managed sixty-nine percent of patients endovascularly and eleven percent through microsurgical clipping. The remaining twenty percent of patients underwent conservative observation. Thus, this extensive dataset establishes vital real-world benchmarks regarding clinical outcomes across diverse tertiary hospital settings.

Ruptured Versus Unruptured Mortality Determinants

Multivariable Cox proportional hazards regression models identified several independent clinical determinants of in-hospital mortality across the cohort. In the overall population, advanced patient age exceeding sixty-five years significantly raised the hazard of death. Similarly, a documented past medical history of subarachnoid hemorrhage markedly increased baseline vulnerability. Presentation with acute aneurysm rupture remained one of the strongest determinants driving patient mortality. Additionally, both treatment-related procedural complications and secondary systemic medical complications substantially worsened patient survival. When investigators analyzed the ruptured aneurysm cohort independently, initial hemorrhage severity dominated the clinical prognosis. Poor clinical grade at hospital admission, thick subarachnoid blood collections, and secondary cerebral ischemia drove early deterioration. Moreover, acute medical complications, including neurogenic pulmonary edema and nosocomial sepsis, accelerated clinical decline in these critically ill patients. Conversely, individuals with unruptured lesions experienced a distinctly different clinical trajectory. In this elective cohort, fatal outcomes rarely stemmed from primary disease progression. Instead, technical procedural mishaps, parent vessel occlusion, intraprocedural rupture, and thromboembolism primarily mediated adverse events. Furthermore, recognizing these distinct pathways assists clinicians in formulating targeted risk-mitigation protocols for both cohorts. Consequently, managing small aneurysms requires targeted neurocritical strategies tailored to each patient’s rupture state.

Impact of Treatment Modalities and Antiplatelet Therapy

The Latin American registry demonstrates a strong preference for endovascular techniques over open microsurgery in contemporary neurovascular practice. Endovascular embolization accounted for sixty-nine percent of all managed cases, reflecting widespread adoption of coiling, flow diversion, and stent-assisted techniques. Nevertheless, open microsurgical clipping maintained an essential role, especially for middle cerebral artery aneurysms with complex branch anatomy. Interestingly, the investigators observed significant differences in clinical outcomes based on antiplatelet therapy administration. Antiplatelet agents play an indispensable role in preventing thromboembolic stroke during stent placement or endoluminal reconstruction. However, the study authors emphasized that clinicians must interpret these antiplatelet findings cautiously. Confounding by indication presents a substantial challenge when analyzing observational neurovascular data. For instance, neurointerventionalists preferentially prescribe dual antiplatelet therapy to patients undergoing complex endovascular procedures who already carry elevated ischemic risks. Furthermore, administering antiplatelet therapy during acute aneurysmal subarachnoid hemorrhage can increase rebleeding risks or complicate ventricular drain placement. Therefore, clinicians must carefully weigh ischemic prevention against hemorrhagic complications when prescribing antiplatelet therapy. Protocolized platelet testing and tailored device selection provide crucial safety margins in these delicate interventional scenarios.

Clinical Implications for Risk Stratification and Practice Optimization

These multicenter findings offer valuable clinical guidance for acute triage, surgical decision-making, and neurointensive care protocols. Clinicians treating older adults over sixty-five years must maintain heightened surveillance, because advanced age markedly magnifies in-hospital mortality. Moreover, emergency physicians must never dismiss small aneurysms when patients present with acute, severe thunderclap headaches. In verified aneurysmal subarachnoid hemorrhage, rapid aneurysm securement prevents catastrophic rebleeding, which carries devastating mortality rates. Simultaneously, neurocritical care teams must aggressively manage secondary complications, including delayed cerebral ischemia, intracranial hypertension, and nosocomial infections. Conversely, when evaluating asymptomatic, unruptured small intracranial aneurysms, physicians must communicate balanced risk estimates. Because elective in-hospital mortality remains low at three percent, preventive intervention requires compelling clinical justification. If an unruptured lesion exhibits regular morphology, stable dimensions, and low rupture scores, conservative surveillance often represents the safest path. In contrast, when intervention becomes necessary, rigorous technical execution is crucial to avoid converting a benign lesion into an iatrogenic disaster. Ultimately, multidisciplinary neurovascular boards combining neurosurgeons, interventional neuroradiologists, and intensivists optimize treatment selection, procedural execution, and patient survival across healthcare systems.

Frequently Asked Questions

What is the primary difference in mortality between ruptured and unruptured small intracranial aneurysms?

In-hospital mortality differs substantially based on rupture status. Patients presenting with ruptured small intracranial aneurysms experience a mortality rate of eighteen percent, driven by initial hemorrhage severity and medical complications. In contrast, unruptured cases exhibit a low three percent mortality rate, which stems primarily from procedural complications during elective intervention.

Which clinical factors independently predict in-hospital mortality in patients with small aneurysms?

Multivariable analysis identifies several independent predictors of in-hospital death. These factors include advanced patient age over sixty-five years, prior aneurysmal subarachnoid hemorrhage, presentation with acute rupture, treatment-related technical complications, and systemic medical complications. Hemorrhage severity dominates risk in ruptured lesions, whereas procedural adverse events dictate outcomes in unruptured cases.

Why should the observed effects of antiplatelet therapy in this cohort be interpreted cautiously?

The relationship between antiplatelet therapy and patient outcomes carries high risk for confounding by indication. Clinicians specifically prescribe potent antiplatelet regimens to complex patients receiving stents or flow diverters. Because these challenging anatomical cases carry intrinsically higher complication risks, retrospective observational data cannot definitively prove whether antiplatelets directly altered patient mortality.

Disclaimer: This content is for informational and educational purposes only and is not intended to serve as medical advice, diagnosis, or treatment. Healthcare professionals must evaluate each patient independently and apply their clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Jaume Favaro A et al. In-hospital mortality in small (≤ 5 mm) intracranial aneurysms: associations with rupture status, treatment, and complications in a multicenter Latin American cohort. Neurosurg Rev. 2026 Sep 29. doi: 10.1007/s10143-026-04517-1. PMID: 42809132.


2. Thompson BG et al. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(8):2368-2400.


3. Connolly ES Jr et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737.


4. UCAS Japan Investigators. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med. 2012;366(26):2474-2482.